PKD1 and prostate carcinoma: Pharmacological inhibition or siRNA-mediated depletion of PKD1 has previously shown cytotoxicity in melanoma, breast cancer, prostate cancer and pancreatic cancer cells [11, 13, 19, 25, 27].